Atlas Trials

Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Clinical trial NCT06054776 · RECRUITING

Trial details

NCT number
NCT06054776
Sponsor
City of Hope Medical Center
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Mantle Cell Lymphoma
Start date
2024-12-02
Primary completion
2026-10-16
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.